MARKET

CDTX

CDTX

Cidara Theraptcs
NASDAQ
11.95
+0.11
+0.93%
Closed 16:00 07/25 EDT
OPEN
11.73
PREV CLOSE
11.84
HIGH
12.15
LOW
11.63
VOLUME
30.63K
TURNOVER
0
52 WEEK HIGH
24.40
52 WEEK LOW
10.00
MARKET CAP
84.11M
P/E (TTM)
-1.4812
1D
5D
1M
3M
1Y
5Y
1D
RA CAPITAL MANAGEMENT, L.P. REPORTS 9.99% STAKE IN CIDARA THERAPEUTICS AS OF JULY 18 - SEC FILING
Reuters · 1d ago
Weekly Report: what happened at CDTX last week (0715-0719)?
Weekly Report · 4d ago
Cidara Therapeutics files for 16.8M common stock offering
Cidara Therapeutics files for 16.8M common stock offering. The company says it is not selling any shares of common stock under the prospectus. Cidara will not receive any proceeds from the sale of the shares in the offering. Company files for up to 16.7M shares of stock.
Seeking Alpha · 07/19 21:27
Cidara Therapeutics Shareholders Decide on Key Corporate Changes
TipRanks · 07/18 20:58
Weekly Report: what happened at CDTX last week (0708-0712)?
Weekly Report · 07/15 10:19
Weekly Report: what happened at CDTX last week (0701-0705)?
Weekly Report · 07/08 10:19
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cidara Therapeutics, Inc. Granted a new employee a non-qualified stock option award and restricted stock units for an aggregate of 10,275 shares of its common stock. The stock option has an exercise price of $11.94 per share. The shares subject to the option will vest over four years.
Barchart · 07/03 12:05
Weekly Report: what happened at CDTX last week (0624-0628)?
Weekly Report · 07/01 10:20
More
About CDTX
Cidara Therapeutics, Inc. is a biotechnology company. The Company is developing targeted immunotherapies designed for patients facing serious diseases. The Company’s portfolio comprises various treatment and prevention paradigms, including drug-Fc conjugate (DFC) from its Cloudbreak platform targeting oncologic, viral and autoimmune diseases. The Company is focused on advancing Cloudbreak development programs, including its lead oncology candidate, CBO421, as well as advancing other pipeline assets. CBO421 is a development candidate targeting CD73 for the treatment of solid tumors. Its advanced DFC program is CD388, a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase I and Phase IIa clinical trials. Its additional programs target multiple autoimmune indications.

Webull offers Cidara Therapeutics Inc stock information, including NASDAQ: CDTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CDTX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CDTX stock methods without spending real money on the virtual paper trading platform.